Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 19/20 | 0.63 |
| ▸ | OXTR | P30559 | 13/20 | 0.63 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703856 | 0.90 | AVPR1A (0.52) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2130122 | 0.90 | AVPR1A (0.74) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL18944418 | 0.89 | AVPR1A (0.51) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2703256 | 0.89 | AVPR1A (0.53) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL18917221 | 0.89 | AVPR1A (0.63) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2628985 | 0.89 | AVPR1A (0.51) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL2128652 | 0.89 | AVPR1A (0.53) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL2130209 | 0.88 | AVPR1A (0.50) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL26185571 | 0.87 | AVPR1A (0.69) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL30045591 | 0.87 | AVPR1A (0.69) | AVPR1AOXTRAVPR2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | claimed |
| US-20070197608-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| EP-1512687-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197608-A1 | Piperazines as oxytocin agonists | OXTR, OPRL1, AVPR2 | AVPR1A 6/4885OXTR 1/4885AVPR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.